Sosum H — LTSR HA Filler for Deep Wrinkles, Jaw, Cheek & Nose (2 x 1ml)

Sosum H is JSBIO’s deep-contouring variant — 20 mg/mL cross-linked HA via patented LTSR technology with the highest density in the standard Sosum range. Lidocaine-free formulation. Engineered for deep dermal to subcutaneous placement: jawline, cheek augmentation, liquid rhinoplasty, deep facial folds. Up to 18 months durability per JSBIO clinical data. Includes 25G + 27G needles.

Sosum H Deep Contouring Dermal Filler is manufactured by JSBIO Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2013. The product is part of the Sosum dermal filler range, which is distributed across multiple international markets. Regulatory status: MFDS approval 2013 · CE certified · GMP.

Sosum H Deep Contouring Dermal Filler contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using JSBIO Co. Ltd.’s Low-Temperature Stabilization Reaction Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per JSBIO Co. Ltd.’s clinical data, Sosum H Deep Contouring Dermal Filler delivers 12-18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep dermis placement typically delivers the longer end of the duration range.

Sosum H Deep Contouring Dermal Filler is engineered for deep dermis · subcutaneous placement. The standard recommended needle is 25G + 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Sosum H Deep Contouring Dermal Filler regulatory status: MFDS approval 2013 · CE certified · GMP. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Sosum H Deep Contouring Dermal Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Sosum H Deep Contouring Dermal Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Sosum H Deep Contouring Dermal Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Yes — Sosum H is one of JSBIO’s recommended variants for non-surgical nose reshaping due to its high cross-linking density and sustained projection capacity. However, liquid rhinoplasty is considered an advanced filler indication with elevated vascular complication risk (especially in the dorsal nasal artery and angular artery regions). Only practitioners with detailed knowledge of nasal vascular anatomy and access to hyaluronidase for emergency dissolution should perform liquid rhinoplasty. Conservative dosing and supraperiosteal placement reduce — but do not eliminate — the vascular risk.